Search

Your search keyword '"Hershkovitz-Rokah, Oshrat"' showing total 29 results
Start Over Author "Hershkovitz-Rokah, Oshrat"
29 results on '"Hershkovitz-Rokah, Oshrat"'

4. Mixed histiocytic neoplasms: A multicentre series revealing diverse somatic mutations and responses to targeted therapy

Author

Friedman, Joshua S., primary, Durham, Benjamin H., additional, Reiner, Anne S., additional, Yabe, Mariko, additional, Petrova‐Drus, Kseniya, additional, Dogan, Ahmet, additional, Pulitzer, Melissa, additional, Busam, Klaus J., additional, Francis, Jasmine H., additional, Rampal, Raajit K., additional, Ulaner, Gary A., additional, Reddy, Ryan, additional, Yeh, Randy, additional, Hatzoglou, Vaios, additional, Lacouture, Mario E., additional, Rotemberg, Veronica, additional, Mazor, Roei D., additional, Hershkovitz‐Rokah, Oshrat, additional, Shpilberg, Ofer, additional, Goyal, Gaurav, additional, Go, Ronald S., additional, Abeykoon, Jithma P., additional, Rech, Karen, additional, Morlote, Diana, additional, Fidai, Shiraz, additional, Gannamani, Vedavyas, additional, Zia, Maryam, additional, Abdel‐Wahab, Omar, additional, Panageas, Katherine S., additional, Rosenblum, Marc K., additional, and Diamond, Eli L., additional

Published
2024
Full Text
View/download PDF

5. Erdheim-Chester disease: consensus recommendations for evaluation, diagnosis, and treatment in the molecular era

Author

Goyal, Gaurav, Heaney, Mark L., Collin, Matthew, Cohen-Aubart, Fleur, Vaglio, Augusto, Durham, Benjamin H., Hershkovitz-Rokah, Oshrat, Girschikofsky, Michael, Jacobsen, Eric D., Toyama, Kazuhiro, Goodman, Aaron M., Hendrie, Paul, Cao, Xin-xin, Estrada-Veras, Juvianee I., Shpilberg, Ofer, Abdo, André, Kurokawa, Mineo, Dagna, Lorenzo, McClain, Kenneth L., Mazor, Roei D., Picarsic, Jennifer, Janku, Filip, Go, Ronald S., Haroche, Julien, and Diamond, Eli L.

Published
2020
Full Text
View/download PDF

6. Supplementary Table S2 from Overcoming Barriers to Tumor Genomic Profiling through Direct-to-Patient Outreach

Author

Doe-Tetteh, Seyram A., primary, Camp, Sabrina Y., primary, Reales, Dalicia, primary, Crowdis, Jett, primary, Noronha, Anne Marie, primary, Wolff, Bernadette, primary, Alano, Tina, primary, Galle, Jesse, primary, Selcuklu, S. Duygu, primary, Viale, Agnes, primary, Socci, Nicholas D., primary, Liu, Ying L., primary, Tew, William P., primary, Aghajanian, Carol, primary, Ladanyi, Marc, primary, He, Meng Xiao, primary, AlDubayan, Saud H., primary, Mazor, Roei David, primary, Shpilberg, Ofer, primary, Hershkovitz-Rokah, Oshrat, primary, Riancho, Jose A., primary, Hernandez, Jose L., primary, Gonzalez-Vela, M. Carmen, primary, Buthorn, Justin J., primary, Wilson, Manda, primary, Webber, Amy E., primary, Yabe, Mariko, primary, Petrova-Drus, Kseniya, primary, Rosenblum, Marc, primary, Durham, Benjamin H., primary, Abdel-Wahab, Omar, primary, Berger, Michael F., primary, Donoghue, Mark T.A., primary, Kung, Andrew L., primary, Glade Bender, Julia, primary, Shukla, Neerav N., primary, Funt, Samuel A., primary, Dogan, Ahmet, primary, Soslow, Robert A., primary, Al-Ahmadie, Hikmat, primary, Feldman, Darren R., primary, Van Allen, Eliezer M., primary, Diamond, Eli L., primary, and Solit, David B., primary

Published
2023
Full Text
View/download PDF

7. Data from Overcoming Barriers to Tumor Genomic Profiling through Direct-to-Patient Outreach

Author

Doe-Tetteh, Seyram A., primary, Camp, Sabrina Y., primary, Reales, Dalicia, primary, Crowdis, Jett, primary, Noronha, Anne Marie, primary, Wolff, Bernadette, primary, Alano, Tina, primary, Galle, Jesse, primary, Selcuklu, S. Duygu, primary, Viale, Agnes, primary, Socci, Nicholas D., primary, Liu, Ying L., primary, Tew, William P., primary, Aghajanian, Carol, primary, Ladanyi, Marc, primary, He, Meng Xiao, primary, AlDubayan, Saud H., primary, Mazor, Roei David, primary, Shpilberg, Ofer, primary, Hershkovitz-Rokah, Oshrat, primary, Riancho, Jose A., primary, Hernandez, Jose L., primary, Gonzalez-Vela, M. Carmen, primary, Buthorn, Justin J., primary, Wilson, Manda, primary, Webber, Amy E., primary, Yabe, Mariko, primary, Petrova-Drus, Kseniya, primary, Rosenblum, Marc, primary, Durham, Benjamin H., primary, Abdel-Wahab, Omar, primary, Berger, Michael F., primary, Donoghue, Mark T.A., primary, Kung, Andrew L., primary, Glade Bender, Julia, primary, Shukla, Neerav N., primary, Funt, Samuel A., primary, Dogan, Ahmet, primary, Soslow, Robert A., primary, Al-Ahmadie, Hikmat, primary, Feldman, Darren R., primary, Van Allen, Eliezer M., primary, Diamond, Eli L., primary, and Solit, David B., primary

Published
2023
Full Text
View/download PDF

8. Supplementary Figure S1 from Overcoming Barriers to Tumor Genomic Profiling through Direct-to-Patient Outreach

Author

Doe-Tetteh, Seyram A., primary, Camp, Sabrina Y., primary, Reales, Dalicia, primary, Crowdis, Jett, primary, Noronha, Anne Marie, primary, Wolff, Bernadette, primary, Alano, Tina, primary, Galle, Jesse, primary, Selcuklu, S. Duygu, primary, Viale, Agnes, primary, Socci, Nicholas D., primary, Liu, Ying L., primary, Tew, William P., primary, Aghajanian, Carol, primary, Ladanyi, Marc, primary, He, Meng Xiao, primary, AlDubayan, Saud H., primary, Mazor, Roei David, primary, Shpilberg, Ofer, primary, Hershkovitz-Rokah, Oshrat, primary, Riancho, Jose A., primary, Hernandez, Jose L., primary, Gonzalez-Vela, M. Carmen, primary, Buthorn, Justin J., primary, Wilson, Manda, primary, Webber, Amy E., primary, Yabe, Mariko, primary, Petrova-Drus, Kseniya, primary, Rosenblum, Marc, primary, Durham, Benjamin H., primary, Abdel-Wahab, Omar, primary, Berger, Michael F., primary, Donoghue, Mark T.A., primary, Kung, Andrew L., primary, Glade Bender, Julia, primary, Shukla, Neerav N., primary, Funt, Samuel A., primary, Dogan, Ahmet, primary, Soslow, Robert A., primary, Al-Ahmadie, Hikmat, primary, Feldman, Darren R., primary, Van Allen, Eliezer M., primary, Diamond, Eli L., primary, and Solit, David B., primary

Published
2023
Full Text
View/download PDF

10. Overcoming Barriers to Tumor Genomic Profiling through Direct-to-Patient Outreach

Author

Doe-Tetteh, Seyram A., primary, Camp, Sabrina Y., additional, Reales, Dalicia, additional, Crowdis, Jett, additional, Noronha, Anne Marie, additional, Wolff, Bernadette, additional, Alano, Tina, additional, Galle, Jesse, additional, Selcuklu, S. Duygu, additional, Viale, Agnes, additional, Socci, Nicholas D., additional, Liu, Ying L., additional, Tew, William P., additional, Aghajanian, Carol, additional, Ladanyi, Marc, additional, He, Meng Xiao, additional, AlDubayan, Saud H., additional, Mazor, Roei David, additional, Shpilberg, Ofer, additional, Hershkovitz-Rokah, Oshrat, additional, Riancho, Jose A., additional, Hernandez, Jose L., additional, Gonzalez-Vela, M. Carmen, additional, Buthorn, Justin J., additional, Wilson, Manda, additional, Webber, Amy E., additional, Yabe, Mariko, additional, Petrova-Drus, Kseniya, additional, Rosenblum, Marc, additional, Durham, Benjamin H., additional, Abdel-Wahab, Omar, additional, Berger, Michael F., additional, Donoghue, Mark T.A., additional, Kung, Andrew L., additional, Glade Bender, Julia, additional, Shukla, Neerav N., additional, Funt, Samuel A., additional, Dogan, Ahmet, additional, Soslow, Robert A., additional, Al-Ahmadie, Hikmat, additional, Feldman, Darren R., additional, Van Allen, Eliezer M., additional, Diamond, Eli L., additional, and Solit, David B., additional

Published
2023
Full Text
View/download PDF

16. Mutant PIK3CAis a targetable driver alteration in histiocytic neoplasms

Author

Durham, Benjamin H., Hershkovitz-Rokah, Oshrat, Abdel-Wahab, Omar, Yabe, Mariko, Chung, Young Rock, Itchaki, Gilad, Ben-Sasson, Maayan, Asher-Guz, Vered A., Groshar, David, Doe-Tetteh, Seyram A., Alano, Tina, Solit, David B., Shpilberg, Ofer, Diamond, Eli L., and Mazor, Roei D.

Abstract

•Activation of PI3K signaling is sufficient to induce a histiocytosis-like disease in vivo at the monocyte/dendritic cell precursor level.•The PI3Kα-specific inhibitor alpelisib shows promising clinical efficacy in PIK3CA-mutant LCH.

Published
2023
Full Text
View/download PDF

17. MicroRNA-15a-5p acts as a tumor suppressor in histiocytosis by mediating CXCL10-ERK-LIN28a-let-7 axis

Author

Weissman, Ran, primary, Diamond, Eli L., additional, Haroche, Julien, additional, Durham, Benjamin H., additional, Cohen, Fleur, additional, Buthorn, Justin, additional, Amoura, Zahir, additional, Emile, Jean-François, additional, Mazor, Roei D., additional, Shomron, Noam, additional, Abdel-Wahab, Omar I., additional, Shpilberg, Ofer, additional, and Hershkovitz-Rokah, Oshrat, additional

Published
2021
Full Text
View/download PDF

20. The Contribution of MicroRNAs to the Inflammatory and Neoplastic Characteristics of Erdheim–Chester Disease

Author

Weissman, Ran, primary, Diamond, Eli L., additional, Haroche, Julien, additional, Pillar, Nir, additional, Shapira, Guy, additional, Durham, Benjamin H., additional, Buthorn, Justin, additional, Cohen, Fleur, additional, Ki, Michelle, additional, Stemer, Galia, additional, Ulaner, Gary A., additional, Amoura, Zahir, additional, Emile, Jean-François, additional, Mazor, Roei D., additional, Shomron, Noam, additional, Abdel-Wahab, Omar I., additional, Shpilberg, Ofer, additional, and Hershkovitz-Rokah, Oshrat, additional

Published
2020
Full Text
View/download PDF

24. Expedient synthesis and anticancer evaluation of dual‐action 9‐anilinoacridine methyl triazene chimeras.

Author

Walunj, Dipak, Egarmina, Katarina, Tuchinsky, Helena, Shpilberg, Ofer, Hershkovitz‐Rokah, Oshrat, Grynszpan, Flavio, and Gellerman, Gary

Subjects
ELECTROPHILIC substitution reactions, TRIAZENES, CELL lines
Abstract

The efficient synthesis of molecular hybrids including a DNA‐intercalating 9‐anilinoacridine (9‐AnA) core and a methyl triazene DNA‐methylating moiety is described. Nucleophilic aromatic substitution (SNAr) and electrophilic aromatic substitution (EAS) reactions using readily accessible starting materials provide a quick entry to novel bifunctional anticancer molecules. The chimeras were evaluated for their anticancer activity. Chimera 7b presented the highest antitumor activity at low micromolar IC50 values in antiproliferative assays performed with various cancer cell lines. In comparison, compound 7b outperformed DNA‐intercalating drugs like amsacrine and AHMA. Mechanistic studies of chimera 7b suggest a dual mechanism of action: methylation of the DNA‐repairing protein MGMT associated with the triazene structural portion and Topo II inhibition by intercalation of the acridine core. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results